Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2007;101:185-194
Published online before print June 7, 2007, doi: 10.1161/CIRCRESAHA.106.146670
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
101/2/185    most recent
CIRCRESAHA.106.146670v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Du, C.-K.
Right arrow Articles by Sasaguri, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Du, C.-K.
Right arrow Articles by Sasaguri, T.
Related Collections
Right arrow Contractile function
Right arrow Remodeling
Right arrow Cardiovascular Pharmacology
Right arrow Animal models of human disease
Right arrow Myocardial cardiomyopathy disease
Right arrow Genetics of cardiovascular disease
Right arrowRelated Article
(Circulation Research. 2007;101:185.)
© 2007 American Heart Association, Inc.


Integrative Physiology

Knock-In Mouse Model of Dilated Cardiomyopathy Caused by Troponin Mutation

Cheng-Kun Du, Sachio Morimoto, Kiyomasa Nishii, Reiko Minakami, Mika Ohta, Naoto Tadano, Qun-Wei Lu, Yuan-Yuan Wang, Dong-Yun Zhan, Misato Mochizuki, Satomi Kita, Yoshikazu Miwa, Fumi Takahashi-Yanaga, Takahiro Iwamoto, Iwao Ohtsuki, Toshiyuki Sasaguri

From the Departments of Clinical Pharmacology (C.-K.D., S.M., Q.-W. L., Y.-Y.W., D.-Y.Z., M.M., Y.M., F.T.-Y., T.S.) and Health Sciences (R.M.), Kyushu University Graduate School of Medicine, Fukuoka, Japan; Department of Cell Biology (K.N.), Tokyo Medical and Dental University; Clinical Genome Informatics Center (M.O.), Kobe University Graduate School of Medicine, Kobe, Japan; Research Laboratory (N.T.), Zenyaku Kogyo Co Ltd, Tokyo, Japan; Department of Pharmacology (S.K., T.I.), Fukuoka University School of Medicine, Fukuoka, Japan; and Department Physiology II (I.O.), Jikei University School of Medicine, Tokyo, Japan.

Correspondence to Sachio Morimoto, PhD, Department of Clinical Pharmacology, Kyushu University Graduate School of Medicine, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. E-mail morimoto{at}med.kyushu-u.ac.jp

We created knock-in mice in which a deletion of 3 base pairs coding for K210 in cardiac troponin (cTn)T found in familial dilated cardiomyopathy patients was introduced into endogenous genes. Membrane-permeabilized cardiac muscle fibers from mutant mice showed significantly lower Ca2+ sensitivity in force generation than those from wild-type mice. Peak amplitude of Ca2+ transient in cardiomyocytes was increased in mutant mice, and maximum isometric force produced by intact cardiac muscle fibers of mutant mice was not significantly different from that of wild-type mice, suggesting that Ca2+ transient was augmented to compensate for decreased myofilament Ca2+ sensitivity. Nevertheless, mutant mice developed marked cardiac enlargement, heart failure, and frequent sudden death recapitulating the phenotypes of dilated cardiomyopathy patients, indicating that global functional defect of the heart attributable to decreased myofilament Ca2+ sensitivity could not be fully compensated by only increasing the intracellular Ca2+ transient. We found that a positive inotropic agent, pimobendan, which directly increases myofilament Ca2+ sensitivity, had profound effects of preventing cardiac enlargement, heart failure, and sudden death. These results verify the hypothesis that Ca2+ desensitization of cardiac myofilament is the absolute cause of the pathogenesis of dilated cardiomyopathy associated with this mutation and strongly suggest that Ca2+ sensitizers are beneficial for the treatment of dilated cardiomyopathy patients affected by sarcomeric regulatory protein mutations.


Key Words: dilated cardiomyopathy • troponin • mutation • calcium sensitivity • knock-in mouse


Related Article:

Translational Medicine With a Capital T, Troponin T, That Is
R. John Solaro
Circ. Res. 2007 101: 114-115. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
Cardiovasc ResHome page
R. Aguilar-Torres
Found in translation: metoprolol improves survival more than carvedilol in a mouse model of inherited dilated cardiomyopathy
Cardiovasc Res, October 1, 2009; 84(1): 7 - 8.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
D.-Y. Zhan, S. Morimoto, C.-K. Du, Y.-Y. Wang, Q.-W. Lu, A. Tanaka, T. Ide, Y. Miwa, F. Takahashi-Yanaga, and T. Sasaguri
Therapeutic effect of {beta}-adrenoceptor blockers using a mouse model of dilated cardiomyopathy with a troponin mutation
Cardiovasc Res, October 1, 2009; 84(1): 64 - 71.
[Abstract] [Full Text] [PDF]


Home page
Circ Heart FailHome page
E. C. Dyer, A. M. Jacques, A. C. Hoskins, D. G. Ward, C. E. Gallon, A. E. Messer, J. P. Kaski, M. Burch, J. C. Kentish, and S. B. Marston
Functional Analysis of a Unique Troponin C Mutation, GLY159ASP, that Causes Familial Dilated Cardiomyopathy, Studied in Explanted Heart Muscle
Circ Heart Fail, September 1, 2009; 2(5): 456 - 464.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. Morimoto
Expanded Spectrum of Gene Causing Both Hypertrophic Cardiomyopathy and Dilated Cardiomyopathy
Circ. Res., August 14, 2009; 105(4): 313 - 315.
[Full Text] [PDF]


Home page
Circ. Res.Home page
S. Carballo, P. Robinson, R. Otway, D. Fatkin, J. D.H. Jongbloed, N. de Jonge, E. Blair, J. P. van Tintelen, C. Redwood, and H. Watkins
Identification and Functional Characterization of Cardiac Troponin I As a Novel Disease Gene in Autosomal Dominant Dilated Cardiomyopathy
Circ. Res., August 14, 2009; 105(4): 375 - 382.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Dweck, N. Hus, and J. D. Potter
Challenging Current Paradigms Related to Cardiomyopathies: ARE CHANGES IN THE Ca2+ SENSITIVITY OF MYOFILAMENTS CONTAINING CARDIAC TROPONIN C MUTATIONS (G159D AND L29Q) GOOD PREDICTORS OF THE PHENOTYPIC OUTCOMES?
J. Biol. Chem., November 28, 2008; 283(48): 33119 - 33128.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Morimoto
Sarcomeric proteins and inherited cardiomyopathies
Cardiovasc Res, March 1, 2008; 77(4): 659 - 666.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. P. Davis and S. B. Tikunova
Ca2+ exchange with troponin C and cardiac muscle dynamics
Cardiovasc Res, March 1, 2008; 77(4): 619 - 626.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
P. Robinson, P. J. Griffiths, H. Watkins, and C. S. Redwood
Dilated and Hypertrophic Cardiomyopathy Mutations in Troponin and {alpha}-Tropomyosin Have Opposing Effects on the Calcium Affinity of Cardiac Thin Filaments
Circ. Res., December 7, 2007; 101(12): 1266 - 1273.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
R. J. Solaro
Translational Medicine With a Capital T, Troponin T, That Is
Circ. Res., July 20, 2007; 101(2): 114 - 115.
[Full Text] [PDF]